# US 2015/0105286 A1 · BLID; a novel protein domain for interaction with the Bcl-2 family of proteins. Applications in Oncology

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105286 A1
- Document ID: US20150105286A1
- Status: Published application
- Kind: A1
- Application number: 14/509,044
- Filed: 2014-10-07
- Published: 2015-04-16
- Earliest claimed: 2011-11-14
- Assignees: Carlos Witte-Hoffmann
- Inventors: Carlos Witte-Hoffmann
- Web page: https://patentgrep.com/patent/US20150105286A1

## CPC

- C07K 14/4747: {Apoptosis related proteins}
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/57575: {involving oncogenic proteins}
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C07K 2319/21: containing a His-tag
- C07K 2319/22: containing a Strep-tag
- C07K 2319/23: containing a GST-tag
- C07K 2319/24: containing a MBP (maltose binding protein)-tag
- C07K 2319/42: containing a HA(hemagglutinin)-tag
- C07K 2319/43: containing a FLAG-tag
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C07K 2319/92: containing an intein ("protein splicing")domain
- G01N 2500/10: involving cells
- G01N 2510/00: Detection of programmed cell death, i.e. apoptosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

In this invention, a novel protein interaction domain is provided along with several of its variants. This domain is involved in protein-protein interactions with the Bcl-2 family of proteins. It is named BLID (Bcl2 family of proteins Like Interaction Domain). Several BLID peptides that could be useful for discovery of drugs to help fight pathological states like cancer are presented.

## Claims

### Claim 1

A method comprising the step of applying to a cell, cell culture or tissue an isolated polypeptide consisting of one or more fragments of the amino acid sequence set forth in SEQ ID NO: 20, wherein said polypeptide is capable of protein-protein interaction with Bcl-2 family proteins, effective to cause apoptosis.

### Claim 2 (depends on 1)

The method of claim 1 wherein the polypeptide is applied as a chimeric polypeptide directly linked to a heterologous polypeptide selected from the group consisting of fluorescent proteins, glutathione-S-transferase, maltose binding protein, beta-galactosidase, inteins, streptavidin, His-tag, myc epitope, HA-tag, and FLAG.

### Claim 3 (depends on 1)

The method of claim 1 wherein the polypeptide is applied as a chimeric polypeptide linked through a heterologous linker consisting of any one of SEQ ID NO: 29 through 32 to a heterologous polypeptide selected from the group consisting of fluorescent proteins, glutathione-S-transferase, maltose binding protein, beta-galactosidase, inteins, streptavidin, His-tag, myc epitope, HA-tag, and FLAG.

### Claim 4 (depends on 1)

The method of claim 1 wherein the polypeptide is applied as a chimeric polypeptide directly linked to a heterologous cell penetrating peptide, and optionally to a heterologous polypeptide selected from the group consisting of fluorescent proteins, glutathione-S-transferase, maltose binding protein, beta-galactosidase, inteins, streptavidin, His-tag, myc epitope, HA-tag, and FLAG.

### Claim 5 (depends on 1)

The method of claim 1 wherein the polypeptide is applied as a chimeric polypeptide directly linked through a heterologous linker consisting of any one of SEQ ID NO: 29 through 32 to a heterologous cell penetrating peptide, and wherein the chimeric polypeptide may optionally include a heterologous polypeptide selected from the group consisting of fluorescent proteins, glutathione-S-transferase, maltose binding protein, beta-galactosidase, inteins, streptavidin, His-tag, myc epitope, HA-tag, and FLAG, said heterologous polypeptide directly linked to the polypeptide or the cell penetrating peptide, or directly linked to the polypeptide or the cell penetrating peptide through the linker consisting of SEQ ID NO: 29 through 32.

### Claim 6 (depends on 1)

The method of claim 1 wherein the applied polypeptide is chemically modified for instance incorporating α/β-amino acid backbones, main chain-to-side chain cross-linking or side chain cross-linking to increase structural stability, cell permeability and serum stability. Examples of these modifications are hydrocarbon stapled polypeptide and biphenyl cross-linked peptides.

### Claim 7 (depends on 1)

The method of claim 1 where the polypeptides are applied to a cell, cell culture or tissue, using for instance an expression or viral vector; to cause the expression of the polypeptides.

### Claim 8 (depends on 1)

The method of claim 1 where the polypeptides are applied to a cell, cell culture or tissue by extrinsically introducing them as purified polypeptides for instance using microinjection or lipofectamine.

### Claim 9 (depends on 1)

The method of claim 1 further including the step of affecting cellular state by subjecting the cells, cell culture or tissue to an apoptotic challenge (i.e. exposure to apoptotic inducing agents like staurosporine, UV irradiation, TRAIL, FasL etc.

### Claim 10 (depends on 9)

The method of claim 9 further including the step wherein in order to screen for the polypeptides's activity, several measures are taken including one or more of the following: measuring the survival rate of the cells, cell culture or tissues; measuring apoptotic markers like chromatin condensation, cellular caspase activity, etc in of the cells, cell culture or tissues and comparing these measurements against controls.

### Claim 11 (depends on 10)

The method of claim 10 further comprising the step of selecting applied polypeptides resulting in a decrease survival rate of the cells, cell culture or tissue when compared with controls as potential drug candidates against pathogenic states where apoptosis is diminished, for instance in cancer.

### Claim 12

A method of using an isolated polypeptide consisting of one or more fragments of the amino acid sequence set forth in SEQ ID NO: 20, wherein said polypeptide is capable of protein-protein interaction with Bcl-2 family proteins in a protein-protein assays such as fluorescence polarization assays, Isothermal titration calorimetry (ITC) and protein microarrays including protein domain microarrays, to measure binding kinetics with members of the Bcl-2 family of proteins in order to select suitable candidates for drug development.

### Claim 13 (depends on 12)

The method of claim 12 further including the step of selecting the polypeptides that result on high-affinity interactions (KD<2 μM), moderate affinity interactions (KD<10 μM) or low-affinity interactions (KD<50 μM) as potential drug candidates against pathogenic states where apoptosis is diminished, for instance in cancer.

### Claim 14 (depends on 12)

The method of claim 12 further including the step of adding combinatorial libraries (chemical combinatorial libraries, combinatorial peptide libraries etc) to the assays to determine their effect on protein-protein interactions involving the polypeptides of claim 12 and members of the Bcl-2 family of proteins.

### Claim 15 (depends on 12, 14)

The method of claim 14 further including the step of selecting the applied molecules of a combinatorial library that results in a disruption of protein-protein interactions involving the polypeptides of claim 12 and members of the Bcl-2 family of proteins when compared with controls, as potential drug candidates against pathogenic states like cancer.

### Claim 16

A method of using an isolated polypeptide consisting of one or more fragments of the amino acid sequence set forth in SEQ ID NO: 20, wherein said polypeptide is capable of protein-protein interaction with Bcl-2 family proteins, in a protein-protein assays such as fluorescence polarization assays, Isothermal titration calorimetry (ITC) and protein microarrays including protein domain microarrays, to measure binding kinetics with the BLID protein domain in order to select suitable candidates for drug development.

### Claim 17 (depends on 16)

The method of claim 16 further including the step of selecting the polypeptides that result on high-affinity interactions (KD<2 μM), moderate affinity interactions (KD<10 μM) or low-affinity interactions (KD<50 μM) as potential drug candidates against pathogenic states where apoptosis is diminished, for instance in cancer.

### Claim 18 (depends on 16)

The method of claim 16 further including the step of adding combinatorial libraries (chemical combinatorial libraries, combinatorial peptide libraries etc) to the assays to determine their effect on protein-protein interactions involving the polypeptides of claim 16 and BLID protein domain.

### Claim 19 (depends on 16, 18)

The method of claim 18 further including the step of selecting the applied molecules of a combinatorial library that results in a disruption of protein-protein interactions involving the polypeptides of claim 16 and BLID protein domain when compared with controls, as potential drug candidates against pathogenic states like cancer.
